金域医学(603882.SH)2019年度净利润预增62.87%到71.44%
格隆汇1月21日丨金域医学(603882.SH)公布,预计2019年度实现归属于上市公司股东的净利润为3.8亿元到4亿元,与上年同期相比,预计增加1.47亿元到1.67亿元,同比增加62.87%到71.44%。
另外,预计2019年度实现归属于上市公司股东的扣除非经常性损益的净利润为2.95亿元到3.15亿元,与上年同期相比,扣除非经常性损益事项后,公司业绩预计增加1.04亿元到1.24亿元,同比增加54.82%到65.32%。
业绩预增的主要原因如下:(一)主营业务影响。2019年公司坚持聚焦医学检验主航道,全面推进高质量发展,优化产品结构及客户结构,加强精细化管理,提升运营效率,经营业绩稳步增长。
(二)非经营性损益的影响。与2018年相比,除政府补助收益外,2019年公司出售全资子公司广州市金圻睿生物科技有限责任公司100%股权,确认投资收益约4500万元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.